Jiangsu Bioperfectus Technologies Co Ltd Asset Resilience Ratio
Jiangsu Bioperfectus Technologies Co Ltd asset resilience ratio. Jiangsu Bioperfectus Technologies Co Ltd (688399) has an Asset Resilience Ratio of 37.23% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Jiangsu Bioperfectus Technologies Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jiangsu Bioperfectus Technologies Co Ltd (2019–2024)
Asset resilience ratio of Jiangsu Bioperfectus Technologies Co Ltd from 2019 to 2024. This chart shows how Jiangsu Bioperfectus Technologies Co Ltd's Asset Resilience Ratio has changed over time. Read 688399 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Bioperfectus Technologies Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Jiangsu Bioperfectus Technologies Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.36 Billion | 37.23% |
| Total Liquid Assets | CN¥1.36 Billion | 37.23% |
Asset Resilience Insights
- Very High Liquidity: Jiangsu Bioperfectus Technologies Co Ltd maintains exceptional liquid asset reserves at 37.23% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Bioperfectus Technologies Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Bioperfectus Technologies Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Jiangsu Bioperfectus Technologies Co Ltd Asset Resilience Ratio by Year (2019–2024)
Jiangsu Bioperfectus Technologies Co Ltd asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Jiangsu Bioperfectus Technologies Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 30.42% | CN¥1.14 Billion ≈ $166.50 Million |
CN¥3.74 Billion ≈ $547.27 Million |
+12.64pp |
| 2023-12-31 | 17.79% | CN¥694.81 Million ≈ $101.67 Million |
CN¥3.91 Billion ≈ $571.63 Million |
-2.96pp |
| 2022-12-31 | 20.75% | CN¥1.01 Billion ≈ $148.51 Million |
CN¥4.89 Billion ≈ $715.71 Million |
+2.94pp |
| 2021-12-31 | 17.81% | CN¥623.33 Million ≈ $91.21 Million |
CN¥3.50 Billion ≈ $512.06 Million |
+4.72pp |
| 2020-12-31 | 13.09% | CN¥298.22 Million ≈ $43.64 Million |
CN¥2.28 Billion ≈ $333.30 Million |
-37.21pp |
| 2019-12-31 | 50.31% | CN¥580.70 Million ≈ $84.98 Million |
CN¥1.15 Billion ≈ $168.92 Million |
-- |
About Jiangsu Bioperfectus Technologies Co Ltd
Jiangsu Bioperfectus Technologies Co., Ltd., a molecular diagnostic company, engages in the research, development, production, and sale of in vitro diagnostic products in China. The company offers in vitro diagnostic reagents and supporting testing equipment, as well as in vitro testing services. It also provides HPV and cervical cancer testing services, respiratory infection detection solution, … Read more